Scientist I/II, In Vivo Pharmacology
Required skills
- postdoctoral
- industry experience
- rodent handling
- multi-route dosing
- blood collection
- survival surgery
- necropsy
- target validation
- efficacy testing
- power analyses
Nice to have
- small biotech
- qPCR
- ddPCR
- ELISA
- LC-MS
- RNAscope
Role summary
Lexeo is seeking an in vivo pharmacologist to develop and utilize rodent models of cardiac disease for target de-risking, therapeutic candidate screening, and pipeline advancement. The role involves designing and executing studies, managing logistics and budgets, and collaborating with cross-functional teams. Responsibilities include establishing disease models, performing dosing and sample collection, analyzing data, and presenting findings. The position requires a PhD or MS with relevant experience in pharmacology or a related field, with hands-on rodent handling, dosing, and surgical skills. Preferred qualifications include experience in biotech, advanced analytical techniques, and specific model systems.
Role Summary
Lexeo is seeking a hands-on in vivo pharmacologist to build rodent models of cardiac disease and use them to de-risk targets, screen therapeutic candidates and advance our discovery pipeline. The scientist will design, perform or manage rodent studies from target validation through hit identification, working cross-functionally with In Vitro Pharmacology, Modality Engineering, and Translational Sciences to select-advance molecules. Reporting to the Head of Cardiac Research, this role joins cardiac, neuroscience, and non-clinical scientists developing therapies for genetic heart disease and offers broad experience in multidisciplinary biopharma research.
Primary Responsibilities
Required Skills and Qualifications
Preferred Skills and Qualifications
About LEXEO
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Similar roles
- Scientist II, Analytical DevelopmentLexeo Therapeutics · New York, NY · Onsite
- Associate Director, MarketingLexeo Therapeutics · New York, NY · Hybrid
- Principal Scientist – Oligonucleotide & AOC Analytical ChemistryAtrium Therapeutics · San Diego, CA · Onsite
- Associate Director, Clinical ScientistKailera Therapeutics · Waltham, MA · Hybrid
- E11 Bio - Scientist I/II, Expansion MicroscopyConvergent Research · Alameda, CA · Onsite
- Research Scientist, Post-Training — Video GenerationPika · United States
